Endocrine effects of inhaled corticosteroids in children

JAMA Pediatrics

Volumn 170, Issue 2, 2016, Pages 163-170

  Kapadia, Chirag R ^a   Nebesio, Todd D ^b   Myers, Susan E ^c   Willi, Steven ^d   Miller, Bradley S ^e   Allen, David B ^f   Jacobson Dickman, Elka ^g  

^a PHOENIX CHILDREN'S HOSPITAL   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^g MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETIRIZINE; CORTICOSTEROID; CORTICOTROPIN; FLUTICASONE PROPIONATE; GLUCOSE; HYDROCORTISONE; MONTELUKAST; PREDNISONE; SALBUTAMOL SULFATE; SALMETEROL XINAFOATE; GLUCOCORTICOID;

ADD ON THERAPY; ADRENAL INSUFFICIENCY; ALLERGY; ASTHMA; BONE DENSITY; CASE REPORT; CHILD; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN TEST; COUGHING; DRUG DOSE REDUCTION; DRY POWDER INHALER; ENDOCRINE DISEASE; FATIGUE; FEMALE; FEVER; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GROWTH DISORDER; GROWTH INHIBITION; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INHALATION; INSULIN DEPENDENT DIABETES MELLITUS; MAINTENANCE THERAPY; MEDICAL HISTORY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT REFERRAL; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD; SIDE EFFECT; THYROID FUNCTION TEST; TONIC CLONIC SEIZURE; CHEMICALLY INDUCED; INHALATIONAL DRUG ADMINISTRATION; METABOLISM;

ADMINISTRATION, INHALATION; ADRENAL INSUFFICIENCY; ASTHMA; BONE DENSITY; CHILD; FEMALE; GLUCOCORTICOIDS; GLUCOSE; HUMANS;

EID: 84956941474     PISSN: 21686203     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapediatrics.2015.3526     Document Type: Review

References (82)

1. Hner M, Hochhaus G, Derendorf H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am. 2005;25(3):469-488.
2. Zlner EW. Hypothalamic-pituitary-Adrenal axis suppression in asthmatic children on inhaled corticosteroids (part 2)-The risk as determined by gold standard adrenal function tests: A systematic review. Pediatr Allergy Immunol. 2007;18(6):469-474.
3. Johnson M. Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol. 1996;97(1, pt 2):169-176.
4. Barnes NC. The properties of inhaled corticosteroids: similarities and differences. Prim Care Respir J. 2007;16(3):149-154.
5. Randell TL, Donaghue KC, Ambler GR, Cowell CT, Fitzgerald DA, van Asperen PP. Safety of the newer inhaled corticosteroids in childhood asthma. Paediatr Drugs. 2003;5(7):481-504.
6. Kannisto S, Korppi M, Remes K, Voutilainen R. Adrenal suppression, evaluated by a low dose adrenocorticotropin test, and growth in asthmatic children treated with inhaled steroids. J Clin Endocrinol Metab. 2000;85(2):652-657.
7. Allen DB. Inhaled corticosteroids and growth: still an issue after all these years. J Pediatr. 2015;166 (2):463-469.
8. Dempsey OJ, Wilson AM, CoutieWJ, Lipworth BJ. Evaluation of the effect of a large volume spacer on the systemic bioactivity of fluticasone propionatemetered-dose inhaler. Chest. 1999;116 (4):935-940.
9. Nair A, Menzies D, Hopkinson P, McFarlane L, Lipworth BJ. In vivo comparison of the relative systemic bioavailability of fluticasone propionate from three anti-static spacers and ametered dose inhaler. Br J Clin Pharmacol. 2009;67(2):191-198.
10. Martin RJSS, Szefler SJ, Chinchilli VM, et al. Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med. 2002;165(10):1377-1383.
11. Minto C, Li B, Tattam B, Brown K, Seale JP, Donnelly R. Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation: intersubject variability in systemic absorption from the lung. Br J Clin Pharmacol. 2000;50(2):116-124.
12. Brutsche MH, Brutsche IC, MunawarM, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: A randomised crossover study. Lancet. 2000;356(9229):556-561.
13. Todd GR, Acerini CL, Ross-Russell R, Zahra S, Warner JT, McCance D. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child. 2002;87(6):457-461.
14. Ahmet A, Kim H, Spier S. Adrenal suppression: A practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy. Allergy Asthma Clin Immunol. 2011;7(7):13.
15. Mortimer KJ, Tata LJ, Smith CJ, et al. Oral and inhaled corticosteroids and adrenal insufficiency: A case-control study. Thorax. 2006;61(5):405-408.
16. Fraser CG, Preuss FS, Bigford WD. Adrenal atrophy and irreversible shock associated with cortisone therapy. J AmMed Assoc. 1952;149(17): 1542-1543.
17. Russell G. Inhaled corticosteroid therapy in children: An assessment of the potential for side effects. Thorax. 1994;49(12):1185-1188.
18. Dluhy RG. Clinical relevance of inhaled corticosteroids and HPA axis suppression. J Allergy Clin Immunol. 1998;101(4 Pt 2):S447-S450.
19. Goldstein DE, Kig P. Effect of inhaled beclomethasone dipropionate on hypothalamic-pituitary-Adrenal axis function in children with asthma. Pediatrics. 1983;72(1):60-64.
20. Katsunuma T, Akasawa A, Iikura Y. Adrenal function of children with bronchial asthma treated with beclomethasone dipropionate. Ann Allergy. 1992;69(6):529-532.
21. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-Analysis. Arch Intern Med. 1999;159(9): 941-955.
22. Patel L, Wales JK, KibirigeMS, Massarano AA, Couriel JM, Clayton PE. Symptomatic adrenal insufficiency during inhaled corticosteroid treatment. Arch Dis Child. 2001;85(4):330-334.
23. Drake AJ, Howells RJ, Shield JPH, Prendiville A, Ward PS, Crowne EC. Symptomatic adrenal insufficiency presenting with hypoglycaemia in children with asthma receiving high dose inhaled fluticasone propionate. BMJ. 2002;324(7345): 1081-1082.
24. Zlner EW. Hypothalamic-pituitary-Adrenal axis suppression in asthmatic children on inhaled corticosteroids, part 1: which test should be used? Pediatr Allergy Immunol. 2007;18(5):401-409.
25. Meakin JW, Grabb J, Bayles TB, Nelson DH. Pituitary-Adrenal function following long-Term steroid therapy. Am J Med. 1960;29(3):459-464.
26. MolimardM, Girodet PO, Pollet C, et al. Inhaled corticosteroids and adrenal insufficiency: prevalence and clinical presentation. Drug Saf. 2008;31(9):769-774.
27. Zlner EW. Hypothalamic-pituitary-Adrenal axis suppression in asthmatic children on inhaled corticosteroids (Part 2)-The risk as determined by gold standard adrenal function tests: A systematic review. Pediatr Allergy Immunol. 2007;18(6):469-474.
28. Klein R, Waldman D, Kershnar H, et al. Treatment of chronic childhood asthma with beclomethasone dipropionate aerosol, I: A double-blind crossover trial in nonsteroiddependent patients. Pediatrics. 1977;60(1):7-13.
29. Vaz R, Senior B, Morris M, Binkiewicz A. Adrenal effects of beclomethasone inhalation therapy in asthmatic children. J Pediatr. 1982;100 (4):660-662.
30. Zlner EWLC, Lombard CJ, Galal U, Hough S, Irusen EM, Weinberg E. Screening for hypothalamic-pituitary-Adrenal axis suppression in asthmatic children remains problematic: A cross-sectional study. BMJ Open. 2013;3(8): e002935.
31. Zlner EWLC, Lombard C, Galal U, Hough S, Irusen E, Weinberg E. Hypothalamic-pituitaryadrenal axis suppression in asthmatic children on inhaled and nasal corticosteroids: more common than expected? J Pediatr Endocrinol Metab. 2011;24 (7-8):529-534.
32. Zlner EWLC, Lombard CJ, Galal U, Hough FS, Irusen EM, Weinberg E. Hypothalamic-pituitaryadrenal axis suppression in asthmatic school children. Pediatrics. 2012;130(6):e1512-e1519.
33. Kamps AW, Molenmaker M, Kemperman R, van der Veen BS, Bocca G, Veeger NJ. Children with asthma have significantly lower long-Term cortisol levels in their scalp hair than healthy children. Acta Paediatr. 2014;103(9):957-961.
34. Zlner EW, Lombard C, Galal U, Hough S, Irusen E, Weinberg E. Hypothalamic-pituitaryadrenal axis suppression in asthmatic children on inhaled and nasal corticosteroids: is the early-morning serum adrenocorticotropic hormone (ACTH) a useful screening test? Pediatr Allergy Immunol. 2011;22(6):614-620.
35. Todd G, Dunlop K, McNaboe J, Ryan MF, Carson D, Shields MD. Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Lancet. 1996;348(9019): 27-29.
36. Kazlauskaite R, Evans AT, Villabona CV, et al; Consortium for Evaluation of Corticotropin Test in Hypothalamic-Pituitary Adrenal Insufficiency. Corticotropin tests for hypothalamic-pituitaryadrenal insufficiency: Ametaanalysis. J Clin Endocrinol Metab. 2008;93(11):4245-4253.
37. Crowley S, Hindmarsh PC, Holownia P, Honour JW, Brook CGD. The use of low doses of ACTH in the investigation of adrenal function in man. J Endocrinol. 1991;130(3):475-479.
38. Kazlauskaite R, MaghnieM. Pitfalls in the diagnosis of central adrenal insufficiency in children. Endocr Dev. 2010;17:96-107.
39. Allen DB. Effects of inhaled steroids on growth, bone metabolism, and adrenal function. Adv Pediatr. 2006;53:101-110.
40. Wolthers OD. Methodology and implications of knemometry in growth assessment of inhaled glucocorticoids. Pediatr Allergy Immunol. 2010; 21(1, pt 2):e190-e198.
41. Wolthers OD, Walters EG. Short-Term lower leg growth in 5-To 11-year-old asthmatic children using beclomethasone dipropionate inhalers with chlorofluorocarbon or hydrofluoroalkane propellants: A 9-week, open-label, randomized, crossover, noninferiority study. Clin Ther. 2011;33 (8):1069-1076.
42. Wolthers OD, Pedersen S. Short-Term growth during treatment with inhaled fluticasone propionate and beclomethasone dipropionate. Arch Dis Child. 1993;68(5):673-676.
43. Agertoft L, Pedersen S. Lower-leg growth rates in children with asthma during treatment with ciclesonide and fluticasone propionate. Pediatr Allergy Immunol. 2010;21(1 Pt 2):e199-e205.
44. Doull IJ, Freezer NJ, Holgate ST. Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate. Am J Respir Crit Care Med. 1995;151(6):1715-1719.
45. Verberne AA, Frost C, Roorda RJ, van der Laag H, Kerrebijn KF; The Dutch Paediatric Asthma Study Group. One year treatment with salmeterol compared with beclomethasone in children with asthma. Am J Respir Crit Care Med. 1997;156(3, pt 1): 688-695.
46. Verberne AA, Frost C, Duiverman EJ, Grol MH, Kerrebijn KF; The Dutch Asthma Study Group. Addition of salmeterol versus doubling the dose of beclomethasone in children with asthma. Am J Respir Crit Care Med. 1998;158(1):213-219.
47. Anthracopoulos MB, Papadimitriou A, Panagiotakos DB, et al. Growth deceleration of children on inhaled corticosteroids is compensated for after the first 12 months of treatment. Pediatr Pulmonol. 2007;42(5):465-470.
48. Saha MT, Laippala P, Lenko HL. Growth of asthmatic children is slower during than before treatment with inhaled glucocorticoids. Acta Paediatr. 1997;86(2):138-142.
49. The Childhood Asthma Management Program Research Group. Long-Term effects of budesonide or nedocromil in children with asthma. N Engl JMed. 2000;343(15):1054-1063.
50. Hoover RMEJ, Erramouspe J, Bell EA, Cleveland KW. Effect of inhaled corticosteroids on long-Term growth in pediatric patients with asthma and allergic rhinitis. Ann Pharmacother. 2013;47(9): 1175-1181.
51. Arend EEFG, Fischer GB, DebiasiM, Schmid H. Inhaled corticosteroid treatment and growth of asthmatic children seen at outpatient clinics. J Pediatr (Rio J). 2006;82(3):197-203.
52. Kelly HW, Sternberg AL, Lescher R, et al; CAMP Research Group. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med. 2012;367 (10):904-912.
53. Raissy HH, Blake K. Does use of inhaled corticosteroid for management of asthma in children make them shorter adults? Pediatr Allergy Immunol Pulmonol. 2013;26(2):99-101.
54. Skversky AL, Kumar J, Abramowitz MK, Kaskel FJ, Melamed ML. Association of glucocorticoid use and low 25-hydroxyvitamin D levels: results from the National Health and Nutrition Examination Survey (NHANES): 2001-2006. J Clin Endocrinol Metab. 2011;96(12): 3838-3845.
55. Tse SMKH, Kelly HW, Litonjua AA, Van Natta ML, Weiss ST, Tantisira KG; Childhood Asthma Management Program Research Group. Corticosteroid use and bone mineral accretion in children with asthma: effect modification by vitamin D. J Allergy Clin Immunol. 2012;130(1): 53-60.e4.
56. Turpeinen M, Pelkonen AS, Nikander K, et al. Bone mineral density in children treated with daily or periodical inhaled budesonide: The Helsinki Early Intervention Childhood Asthma study. Pediatr Res. 2010;68(2):169-173.
57. Harris M, Hauser S, Nguyen TV, et al. Bone mineral density in prepubertal asthmatics receiving corticosteroid treatment. J Paediatr Child Health. 2001;37(1):67-71.
58. Kelly HW, Van Natta ML, Covar RA, Tonascia J, Green RP, Strunk RC; CAMP Research Group. Effect of long-Term corticosteroid use on bone mineral density in children: A prospective longitudinal assessment in the childhood Asthma Management Program (CAMP) study. Pediatrics. 2008;122(1): e53-e61.
59. Sharma PK, Malhotra S, Pandhi P, Kumar N. Effect of inhaled steroids on bone mineral density: Ameta-Analysis. J Clin Pharmacol. 2003;43(2): 193-197.
60. Gregson RK, Rao R, Murrills AJ, Taylor PA, Warner JO. Effect of inhaled corticosteroids on bone mineral density in childhood asthma: comparison of fluticasone propionate with beclomethasone dipropionate. Osteoporos Int. 1998;8(5):418-422.
61. Rao R, Gregson RK, Jones AC, Miles EA, CampbellMJ, Warner JO. Systemic effects of inhaled corticosteroids on growth and bone turnover in childhood asthma: A comparison of fluticasone with beclomethasone. Eur Respir J. 1999;13(1):87-94.
62. Altintas DU, Karakoc GB, Can S, Yilmaz M, Kendirli SG. The effects of long term use of inhaled corticosteroids on linear growth, adrenal function and bone mineral density in children. Allergol Immunopathol (Madr). 2005;33(4):204-209.
63. Allen HD, Thong IG, Clifton-Bligh P, Holmes S, Nery L, Wilson KB. Effects of high-dose inhaled corticosteroids on bone metabolism in prepubertal children with asthma. Pediatr Pulmonol. 2000;29 (3):188-193.
64. Griffiths AL, Sim D, Strauss B, Rodda C, Armstrong D, Freezer N. Effect of high-dose fluticasone propionate on bone density and metabolism in children with asthma. Pediatr Pulmonol. 2004;37(2):116-121.
65. Weldon D. The effects of corticosteroids on bone growth and bone density. Ann Allergy Asthma Immunol. 2009;103(1):3-11.
66. Abrams SA. Dietary guidelines for calcium and vitamin D: A new era. Pediatrics. 2011;127(3):566-568.
67. Turpeinen M, Sorva R, Juntunen-Backman K. Changes in carbohydrate and lipid metabolism in children with asthma inhaling budesonide. J Allergy Clin Immunol. 1991;88(3 Pt 1):384-389.
68. Willi SM, Kennedy A, Wallace P, Ganaway E, Rogers NL, GarveyWT. Troglitazone antagonizes metabolic effects of glucocorticoids in humans: effects on glucose tolerance, insulin sensitivity, suppression of free fatty acids, and leptin. Diabetes. 2002;51(10):2895-2902.
69. Slatore CG, Bryson CL, Au DH. The association of inhaled corticosteroid use with serum glucose concentration in a large cohort. Am J Med. 2009; 122(5):472-478.
70. Pagano G, Cavallo-Perin P, Cassader M, et al. An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. J Clin Invest. 1983;72(5):1814-1820.
71. Ranta F, Avram D, Berchtold S, et al. Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4. Diabetes. 2006;55(5):1380-1390.
72. Lambillotte C, Gilon P, Henquin JC. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest. 1997;99(3):414-423.
73. Faul JL, Wilson SR, Chu JW, Canfield J, KuschnerWG. The effect of an inhaled corticosteroid on glucose control in type 2 diabetes. Clin Med Res. 2009;7(1-2):14-20.
74. OByrne PM, Rennard S, Gerstein H, et al. Risk of new onset diabetes mellitus in patients with asthma or COPD taking inhaled corticosteroids. Respir Med. 2012;106(11):1487-1493.
75. Kiviranta K, Turpeinen M. Effect of eight months of inhaled beclomethasone dipropionate and budesonide on carbohydrate metabolism in adults with asthma. Thorax. 1993;48(10):974-978.
76. Kruszynska YT, Greenstone M, Home PD, Cooke NJ. Effect of high dose inhaled beclomethasone dipropionate on carbohydrate and lipid metabolism in normal subjects. Thorax. 1987; 42(11):881-884.
77. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123(11):1001-1006.
78. Yucel O, Eker Y, Nuhoglu C, Ceran O. Hemoglobin a1c levels in children with asthma using low dose inhaled corticosteroids. Indian Pediatr. 2009;46(4):300-303.
79. Wright NP, Wales JK. The incidence of hypoglycaemia in children with type 1 diabetes and treated asthma. Arch Dis Child. 2003;88(2):155-156.
80. Shah S, Kublaoui BM, Oden JD, White PC. Screening for type 2 diabetes in obese youth. Pediatrics. 2009;124(2):573-579.
81. Kapadia CR. Are the ADA hemoglobin A(1c) criteria relevant for the diagnosis of type 2 diabetes in youth? Curr Diab Rep. 2013;13(1):51-55.
82. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol. 2007;120(5 suppl):S94-S138.